2008-2009年玉林市部分非淋球菌性尿道炎患者感染支原体检测及药敏分析

目的]了解非淋球菌性尿道炎（NGU）患者的支原体感染及药敏情况，为临床正确用药提供参考。方法]对2008～2009年到玉林市疾病预防控制中心诊治的1262例门诊疑为NGU患者进行支原体培养及药敏分析。采用支原体药敏试剂盒检测支原体．观察药敏结果。结果]1262例NGU疑似患者标本中支原体培养阳性者532例，阳性率为42．16％。532例支原体阳性者中，单纯解脲支原体（Uu）感染371例，占69．74％；单纯人型支原体（Mh）感染25例，占4．70％；Uu＋Mh混合感染136例，占25．56%。1262例患者中男性606例．女性656例，男女性支原体感染阳性率分别为26，24％、56．86%，差异有统计学意义（P〈0．01）。单纯Uu感染者其约物敏感性最高的为交沙霉素（95.15％），其次为环脂红霉素（90．30%）．耐药率最高为环丙沙星（64．15％）；单纯Mh感染者其敏感性最高的为美满霉素（100．00％），其次为交沙霉索（80．00％）．耐药率最高的为阿奇霉素，罗红霉素均为（84．00％）；Uu-Mh混合感染者，敏感性最高的是交沙霉素（86．76％），其次为强力霉素（79．41%），耐药率最高的为环丙沙星（81.62％）。结论J支原体感染以单纯Uu感染最为普通，临床应根据药敏结果合理选择抗生素，以有效控制泌尿牛殖道支原体的感染。

Detection of Non-gonococcal Urethritis Patients Infected with Mycoplasma and Test of Drug Sensitivity in Yulin City, 2008-2009

Objective]To understand the mycoplasma infection and the drug sensitivity of non gonococcal urethritis patients and provide reference for correct clinical medication. Methods]To observe the resuhs of drug sensitivity,mycoplasma was tested by a drug sensitivity kit.Results]Of the 1 262 cases,532 were detected mycoplasma positive,with a positive rate of 12.16%,including 371 cases positive for Ureaplasma urealyticum （Uu） （69. 74%）,25 cases positive for Mycoplasma hominis （Mh） （1.70% ）,and 136 cases positive for two Ureaplasma mixed infection（25.56% ）. Of the 1 262 ca ses,606 cases were male patients and 656 cases were female patients.the difference in the positive rate between male and female patients had statistic significance（ P 〈0.01）. Uu was sensitive to Josamycin（95.15%）and Cycloate Erythromycin （90.30%）;Mh was sensitive to Minocycline（100.00%）and ,losamycin（80.00%）;the mixed infect ions of Uu＋ Mh was sensitive to Josamycin（86.76%）and Doxycycline（79. 11%）. Uu and Uu＋ Mh were most resistant to Ciprofloxacin （64. 15%）and Ciprofloxacin（81.62%）： Mh were both most resistant to Azithromycin （84.00%）and Roxithromycin （84.00%）. Conclusion]Mycoplasma infection is dominated by Uu,and rational selection of antibiotics based on the results of drug sensitivity test will be important for effective control of mycoplasma infection in the urino-genital tracts.